Copolymer-1 improvements in compositions of copolymers
AssigneeYeda Research and Development Co. Ltd.
InventorsEliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
Life of this patent
Estimating the term…
Abstract
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
Claims16
A copolymer-1 fraction substantially free of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
A copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
A copolymer-1 fraction, wherein said copolymer-1 has an average molecular weight of about 4 to about 8 kilodaltons.
A copolymer-1 fraction, wherein said copolymer-1 has an average molecular weight of about 6.25 to about 8.4 kilodaltons.
A composition for the treatment of multiple sclerosis, comprising
- a pharmaceutically effective amount of a copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons, and
- a pharmaceutically acceptable carrier.
A composition for the treatment of multiple sclerosis, comprising
- a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 4 to about 8 kilodaltons, and
- a pharmaceutically acceptable carrier.
A composition for the treatment of multiple sclerosis, comprising
- a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 6.25 to about 8.4 kilodaltons, and
- a pharmaceutically acceptable carrier.
A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said fraction contains less than 5% of species of copolymer-1 having a molecular weight of over 40 kilodaltons.
A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 4 to about 8 kilodaltons.
A method for treating multiple sclerosis, comprising administering to a subject in need thereof a pharmaceutically effective amount of a copolymer-1 fraction, wherein said copolymer-1 in said fraction has an average molecular weight of about 6.25 to about 8.4 kilodaltons.
Dependencies are inferred from the claim text.